Company news
Adalta Ltd. (ASX:1AD) news
Adalta Ltd. news releases on 6ix. Latest, Apr 8, 2024: SYNThesis BioVentures MoU for cellular immunotherapies
Press releases — page 2
SYNThesis BioVentures MoU for cellular immunotherapies
April 7, 2024
Corporate Presentation
March 7, 2024
Positive AD-214 Phase I extension study results
March 5, 2024
January 2024 partnering presentations and progress
January 21, 2024
New malaria inhibiting i-body
December 18, 2023
Chair address and CEO presentation to AGM
November 21, 2023
AD-214 Phase I extension clinical study - interim results
November 20, 2023
AdAlta closes oversubscribed $1.65 million raise
November 8, 2023
Oversubscribed placement result
November 6, 2023
Placement to raise up to $1.23million
November 2, 2023
AD-214 well tolerated in Phase I extension study
October 22, 2023
R&D tax refund received & R&D Loan repayment terms extended
October 17, 2023
Prof Foley invited presentation AD-214
September 25, 2023
Dosing simulations support AD-214 IV product profile
September 24, 2023
AD-214 Phase I extension study fully enrolled
September 19, 2023
AdAlta to Present at August 24th Virtual Investor Summit
August 16, 2023
AD-214 returns to clinic
August 3, 2023
$1.87 million raised in oversubscribed Shortfall facility
July 12, 2023
New AD-214 data de-risks clinical studies
July 6, 2023
AD-214 clinical trial approval
June 28, 2023
AdAlta to present at June 1 Virtual Investor Summit
May 30, 2023
AdAlta secures A$1.28 million in rights offer to advance AD-214
May 25, 2023
Rights Offer results
May 24, 2023
AdAlta to support early return to clinical trials of AD-214 with rights offer
May 1, 2023
Rights Offer to fund early return to clinic and growth
April 27, 2023
Publication highlights I-body potential in osteoporosis
January 24, 2023
AdAlta welcomes new substantial shareholders
January 23, 2023
Second Japan patent for AD-214
January 9, 2023
AD-214 progress and priorities webinar presentation
November 1, 2022
AD-214 progress and priorities
November 1, 2022
Balance of R&D Tax Incentive Refund received
October 26, 2022
1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancer
October 12, 2022
R&D Tax Incentive Refund received
October 3, 2022
AdAlta : Quarterly Appendix 4C and Activities Report
July 24, 2022
AD-214 program update, cash runway extension
July 3, 2022
European Patent for AD-214 granted
June 13, 2022
BIO International Convention presentation
May 31, 2022
AdAlta presentation at Bioshares Biotech Summit
May 9, 2022
Indian patent for AD-214
April 6, 2022
Inhaled AD-214 preclinical program
April 4, 2022
PAC Partners Healthcare Conference - Corporate Presentation
April 4, 2022
$1.6M Second Tranche R&D Cash Flow Loan Received
March 8, 2022
Chinese patent granted for AD-214
March 1, 2022
AdAlta : Change in Director Interest Notice x 4
February 10, 2022
AdAlta : Application for quotation of securities - 1AD
February 6, 2022
Entitlement Offer Results
February 3, 2022
AdAlta : Presentation to Share Cafe Webinar
January 19, 2022
AdAlta : Presentation Conference Schedule - January 2022
January 3, 2022
Entitlement Offer Booklet
December 22, 2021
Reinstatement to Quotation
December 14, 2021